



07 July 2022

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

technegas
ultralute

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Independent multicentre study highlights the benefits of Technegas™ in diagnosing Pulmonary Embolism in growing COVID-19 patient population

Cyclopharm Limited (ASX: CYC) today advises an independent French multicentre study has reaffirmed the Company's proprietary technology, Technegas™, plays a key role in diagnosing pulmonary embolism in COVID-19 patients and was used ahead of competitor products in 92% of cases evaluated.

The Independent French Study:

- **Reinforces the importance of nuclear medicine ventilation imaging using Technegas™ in ruling out Pulmonary Embolism (PE) in patients with COVID-19;**
- **Highlights the use of Technegas™ as the predominant ventilation imaging agent (92%) used by clinicians in this study, and the importance of Technegas™ in the everyday practice of nuclear medicine imaging;**
- **Compliments the work recently published by McMaster University in the use of Technegas™ in diagnosing and managing patients suffering from Long COVID;**
- **Supports the Company's strategy to extend engagement beyond its current core nuclear medicine customers to respiratory and emergency medicine referrers globally; and**
- **Substantiates Cyclopharm's new market opportunity - 'Beyond PE' where Technegas™ can play a critical role in wider indications such as asthma and COPD.**

In a collaboration between the French Society of Nuclear Medicine and French clinicians, the independent study, titled "**Lung Scintigraphy for Pulmonary Embolism Diagnosis in COVID-19 Patients: A Multicenter Study,**" was published in the July 2022 edition of the United States Journal of Nuclear Medicine¹, by the Society of Nuclear Medicine and Molecular Imaging. The research was conducted in France over 12 sites and involved 183 patients. The results showed Technegas™ ventilation imaging was used ahead of competitive products in COVID-19 patients in 92% of the patient cases evaluated.

Over 530 million people worldwide are estimated to have had COVID-19 by June 2022, resulting in more than 6.3 million deaths.² Although most people with COVID-19 recover fully, some have longer term symptoms (Long COVID)—usually persisting beyond 35 weeks.³ Both the definition and estimated prevalence of long covid vary widely, but one recent international systematic review of studies reported that around 43% of adults with covid-19 still have at least one symptom 28 days after infection, rising to 57% among those admitted to hospital.⁴

¹ Journal of Nuclear Medicine July 2022, 63 (7) 1070-1074; DOI: <https://doi.org/10.2967/jnumed.121.262955>

² Johns Hopkins University of Medicine. Coronavirus Resource Centre. 3 Jun 2022. <https://coronavirus.jhu.edu/map.html>

³ Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*2021;38:101019. doi:10.1016/j.eclinm.2021.101019. pmid:34308300

⁴ Chen C, Haupt SR, Zimmermann L, et al. Global prevalence of post-coronavirus disease 2019 (covid-19) condition or long covid: a meta-analysis and systematic review. *J Infect Dis*2022. doi:10.1093/infdis/jiac136. pmid:35429399

The outcomes of the French study support recent research announced by the Company to the ASX on 24 May 2022⁵, titled, “New peer reviewed study reveals Technegas™ potential as a valuable tool for the diagnosis and management of ‘Long COVID’” which demonstrated the benefits of Technegas™ as a valuable tool for the diagnosis and management of Long COVID in this evolving group of related post-infection symptoms.

Cyclopharm Managing Director and CEO, James McBrayer, said, “Results from this independent study supports the importance of Technegas™ in the diagnosis of PE in patients suffering from COVID and highlights the further potential use in this growing patient population⁶. Independent, highly credible published studies such as these are playing a key role in the growing demand for Technegas™, as clinicians seek to utilise its benefits in managing the impacts of their patients’ COVID-19 infections.”

“This Study combined with the recent Long COVID study by McMaster University emphasises the clinical significance of Technegas™ and its growth potential across the 63 countries in which the product is available. It also underscores the tangible potential of our Beyond PE initiatives in the diagnosis and patient management into indications such as Long COVID, COPD, asthma and lung cancer. ”

[ENDS]

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please refer to our website at www.cyclopharm.com or contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas™ used in functional lung ventilation imaging.

Technegas™

The Technegas™ technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas™, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

⁵ “Technegas used in Diagnosing Long Covid”, Release via ASX on 24 May 2022

⁶ “Cyclopharm Limited, Preliminary Final report”, Release via the ASX on 27, Feb 2019.